EMBECTA CORP. Deferred Foreign Income Tax Expense (Benefit)
EMBECTA CORP. (EMBC) reported Deferred Foreign Income Tax Expense (Benefit) of $10.30 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2025-11-25
- EMBECTA CORP. deferred foreign income tax expense (benefit) for fiscal 2025 was $10.30M.
- EMBECTA CORP. deferred foreign income tax expense (benefit) for fiscal 2024 was -$21.90M, a 384.42% decline from fiscal 2023.
- EMBECTA CORP. deferred foreign income tax expense (benefit) for fiscal 2023 was $7.70M, a 16.30% decline from fiscal 2022.
- EMBECTA CORP. deferred foreign income tax expense (benefit) for fiscal 2022 was $9.20M.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-09-30 | $10.30M 10-K · filed 2025-11-25 |
| 2024-09-30 | -$21.90M 10-K · filed 2025-11-25 |
| 2023-09-30 | $7.70M 10-K · filed 2025-11-25 |
| 2022-09-30 | $9.20M 10-K · filed 2024-12-11 |
| 2021-09-30 | -$1.20M 10-K · filed 2023-11-29 |
| 2020-09-30 | $500.00K 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |